cetuximab + irinotecan hydrochloride + ramucirumab

This is a combination regimen consisting of three agents—cetuximab, irinotecan hydrochloride, and ramucirumab—used in the treatment of metastatic colorectal cancer (mCRC), particularly as a second-line therapy for patients with KRAS wild-type tumors who have progressed after first-line oxaliplatin- and bevacizumab-based regimens. - Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting downstream signaling involved in tumor cell proliferation and survival. - Irinotecan hydrochloride is a small molecule topoisomerase I inhibitor that interferes with DNA replication in cancer cells, leading to cell death. - Ramucirumab is a fully human monoclonal antibody directed against vascular endothelial growth factor receptor 2 (VEGFR2), blocking angiogenesis required for tumor growth. The rationale for this combination is to simultaneously inhibit EGFR-mediated signaling, disrupt DNA replication, and block angiogenesis pathways to improve progression-free survival in advanced mCRC following failure of standard first-line therapies[1][3]. Clinical studies suggest this regimen may prolong progression-free survival but can be associated with increased toxicity[1][3].

Other names

ICR